Table 1 Main characteristics of the included studies in this meta-analysis
Study | Country | Cancer type | Sample size | Sex of patients (male /female) | Mean or median age (years) | Study period | Mean or median follow-up (months) | Clinical outcome | CD9 detection | Cut-off value of CD9 expression | Survival analysis | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baek et al. [6] | South Korea | Invasive lobular carcinoma | 113 | NA | 48 (27–88) | 2001–2013 | 62 (7–187) | DFS | IHC | Staining scores with intensity and proportion (≥ 4) | MVA | 8 |
Touzet et al. [7] | France | Acute myeloid leukemia | 112 | 61/51 | 51.9 (20.9–77.6) | 2009–2016 | NA | OS, RFS | Flow cytometry | 20% of all the blasts | UVA(OS) MVA(RFS) | 7 |
Liang et al. [22] | China | Acute lymphoblastic leukemia | 112 | 48/64 | 39.46 | 2013–2016 | NA | OS | Flow cytometry | 20% of all the blasts | MVA | 7 |
Kwon et al. [21] | South Korea | Invasive breast cancer | 1349 | NA | NA | 1995–2007 | 115 (1–233) | DFS | IHC | Staining scores with intensity and proportion (4) | MVA | 8 |
Kim et al. [10] | South Korea | Colorectal carcinoma | 304 | 163/141 | NA | 1996–2000 | 4–243 | DFS | IHC | Staining scores with intensity and proportion (3) | MVA | 8 |
Dong et al. [20] | China | Follicular lymphoma | 76 | 32/44 | 50.90 (25–76) | 2006–2013 | NA | PFS | IHC | Staining scores with intensity and proportion (3) | UVA | 6 |
Amatya et al. [19] | Japan | Malignant mesothelioma | 112 | 103/9 | 65.8 (42–88) | NA | 16.5 (0–79) | OS | IHC | Negative: no staining | MVA | 8 |
Zou et al. [13] | China | Gallbladder adenocarcinoma | 108 | 24/84 | 52.6 (35–70) | 1996–2006 | NA | OS | IHC | 25% | MVA | 7 |
Mhawech et al. [15] | Switzerland | Head and neck squamous cell carcinoma | 153 | 122/31 | 59 (35–90) | 1992–1999 | 65 (14–123) | DFS | IHC | 50% | MVA | 8 |
Hashida et al. [11] | Japan | Colon cancer | 146 | 84/62 | 62.8 (35–80) | 1994–2001 | 44.3 (6.3–85.9) | OS, DFS | IHC | Staining scores with intensity and proportion (120) | MVA | 8 |
Erovic et al. [16] | Austria | Head and neck squamous cell carcinoma | 34 | 27/7 | 56 (42–77) | 1985–2001 | 0–92 | OS, DFS | IHC | 50% | UVA(OS) MVA(DFS) | 8 |
Mhawech et al. [18] | Switzerland | Urothelial bladder carcinoma | 320 | 257/63 | 70.4 (27–98) | 1988–1999 | 43.6 (112–240) | RFS | IHC | 5% | MVA | 8 |
Shimada et al. [12] | Japan | Eaophageal squamous cell carcinoma | 116 | 98/18 | 63.9 | 1987–1995 | 5.69 | OS | IHC | 50% | MVA | 8 |
Huang et al. [9] | Japan | Breast cancer | 109 | NA | NA | 1987–1995 | 48.5 | OS, DFS | RT-PCR | Positive/Negative | MVA | 8 |
Sho et al. [14] | Japan | Pancreatic cancer | 40 | 31/9 | 66 (47–80) | 1992–1997 | 22.9 (5–62) | OS | RT-PCR | Positive/Decreased | MVA | 8 |
Miyake et al. [8] | Japan | Breast cancer | 143 | NA | NA | 1990–1992 | 45.7 (30–61) | OS, DFS | IHC | 50% | MVA | 8 |
Higashiyama et al. [17] | Japan | Non-small cell lung cancer | 109 | 80/29 | NA | 1991–1992 | 43.7 (31–55) | OS | RT-PCR | Positive/Negative | MVA | 8 |